Overview of the New International CSU Guidelines and Expanded Treatment

The updated international guidelines for chronic spontaneous urticaria (CSU) represent the most substantive revision to the treatment algorithm since the 2022 iteration, most notably with the formal incorporation of dupilumab and remibrutinib as recommended step-up therapies alongside omalizumab for patients inadequately controlled on high-dose antihistamines. This expansion is clinically significant given that approximately 50% of CSU patients fail antihistamine-based regimens regardless of dose escalation. Dupilumab, an interleukin-4 receptor alpha (IL-4Rα) antagonist with established use across multiple type 2 inflammatory conditions, brings a known safety profile and approval down to age 12, while remibrutinib offers a novel oral Bruton tyrosine kinase (BTK) inhibitory mechanism with demonstrated rapid onset of action in adult patients.

The practical implications differ by specialty. In dermatology, where high patient volume and workflow considerations have historically limited omalizumab utilization — including the agent's black-box warning, which does not apply to the urticaria indication, and the burden of clinic wait times — having an oral agent and a biologic with broader prescribing familiarity may substantially expand the pool of patients receiving guideline-concordant step-up therapy. In allergy/immunology, where omalizumab has been used more routinely, these new agents enrich the shared decision-making framework by allowing clinicians to tailor therapy to individual patient preferences, comorbidities, and logistical factors such as medication preparation and administration burden.

In this video discussion on CSU guideline updates, Jason Hawkes, MD, dermatologist at Oregon Medical Research Center and an author on the new guidelines, and Nicole Chase, MD, an allergist/immunologist in private practice and associate professor of medicine at the University of Minnesota, examine what these changes mean for clinicians across both specialties. Both experts emphasize that expanding the available options is not simply a matter of convenience — it directly addresses longstanding gaps in care for a population that has had limited recourse when antihistamine strategies have failed, and that the availability of a fast-acting oral agent alongside 2 established biologics meaningfully changes the conversation clinicians can have with patients about what relief is realistically achievable.